BioSpace News Archive

Oramed Pharmaceuticals Inc. announced the European Patent Office has granted the Company a patent titled “Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same.”

Invitae Corporation will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 , at 9:45 a.m. Eastern Time .

KeifeRx, LLC, an emerging clinical-stage biopharmaceutical company specializing in the discovery and development of new treatment options for neurodegenerative diseases, announced that the Company is participating in the H.C. Wainwright BioConnect 2022 Conference and BIO Partnering at JPM.

AlloVir today announced that the U.S. Food and Drug Administration (FDA) has granted its lead multi-virus specific T cell (VST) therapy, posoleucel (Viralym-M, ALVR105), Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of adenovirus (AdV) infection following allogeneic hematopoietic stem cell transplant (allo-HCT).

Alterity Therapeutics announced that David Stamler, M.D., Chief Executive Officer will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022.

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the 40th Annual J.P. Morgan Healthcare Conference.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated therapeutics, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12th at 3:00 p.m. ET.

Cue Biopharma, Inc. (Nasdaq: CUE), along with LG Chem Life Sciences, announced today that a key milestone in the selection of a clinical product candidate has been reached in their collaboration for CUE-102, an Immuno-STAT™ biologic, jointly developed to selectively target WT1-expressing cancers.

SalioGen Therapeutics, a privately held biotechnology company developing Gene Coding™, a new category of genetic medicine, today announced the completion of an oversubscribed and up-sized $115 million Series B financing.

Icosavax, Inc., a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop vaccines against infectious diseases, announced the appointment of John Shiver, Ph.D., to its Board of Directors.